No quarterly revenue total was found in ENLIVEN THERAPEUTICS, INC.'s SEC filings.
Enliven Therapeutics, Inc. (ELVN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$12.6 million. As of Sep 30, 2026 it held $884.4 million in cash and investments and $1.3 million in total debt.
Revenue
—
Net income
$-27.70M
-37.5% vs year-ago quarter
Operating cash flow
$-12.55M
+5.5% vs year-ago quarter
Free cash flow
$-12.65M
+4.8% vs year-ago quarter
EPS
$-0.36
-12.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
73.60M
+24.0% vs year-ago quarter
Net cash
$883.04M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELVN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Burlingame, CA
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1672619
- Former names
- IMARA Inc. (until Feb 23, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$36.0M | -$37.2M | -$27.8M | -$34.3M | -$25.1M |
| Net income | -$27.7M | -$32.5M | -$23.6M | -$29.7M | -$20.1M |
| Diluted EPS | -$0.36 | -$0.49 | -$0.38 | -$0.48 | -$0.32 |
| Operating cash flow | -$12.6M | -$18.5M | -$19.3M | -$15.8M | -$13.3M |
| Free cash flow | -$12.6M | -$18.6M | -$19.3M | -$15.8M | -$13.3M |
| Total assets | $897.2M | $910.2M | $464.9M | $476.2M | $490.9M |
| Total liabilities | $20.3M | $15.1M | $11.5M | $16.6M | $14.8M |
| Stockholders' equity | $876.9M | $895.1M | $453.4M | $459.6M | $476.1M |
| Cash and investments | $884.4M | $895.2M | $452.4M | $462.6M | $477.6M |
| Total debt | $1.3M | $1.5M | $302,000 | $399,000 | $490,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 14, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 12, 2026 | Jun 11, 2026 |
All 798 Enliven Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.